Join us for an insightful session on how AI is transforming immunogenicity assay workflows and decision-making in drug development—paired with a look at evolving AI regulations in the US and EU.
Considerations for the Use of Artificial Intelligence to Support Decision-Making for Drug and Biological Products
Vibha Jawa, PhD, FAAPS, Bristol Myers Squibb, and Stephanie Pasas-Farmer, PhD, BioData Solutions
Friday, June 6 | 2:15 PM
South Street Landing Conference Center, Providence, Rhode Island
Upcoming & Recent Events
News
0